BABCP response to the Royal College of Psychiatrists (RCPsych) report on Psychedelic and related substances for medical use
Commenting on the report, Dr Stirling Moorey, President of the British Association for Behavioural and Cognitive Psychotherapies (BABCP) said: “We welcome the publication of the report by the RCPsych which highlights the need for further research in the area of efficacy of psychedelic and related substances (PARS) to treat a range of mental illnesses.
“As the lead membership organisation for Cognitive Behavioural Therapy (CBT) in the UK and Ireland, we believe that the potential therapeutic use of psychedelic and related substances (PARS) would still require Talking Therapies, such as CBT alongside the medication. As the report states, the therapeutic effects of many of these compounds are likely to be a result of the interaction between the pharmacological effects of the substance and the therapeutic relationship.
“We are committed to providing the best available evidence-based treatment possible to clients, and as such, we are committed to working with the Royal College of Psychiatrists to develop specific training standards as required.”
